Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology
Carlos Escobar(Hospital Prof. Dr. Fernando Fonseca), José Luis Zamorano(Hospital Universitario Ramón y Cajal), Leopoldo Pérez de Isla(Hospital Clínico San Carlos), Isabel Egocheaga, Xavier Pintó(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Vicente Arrarte(Hospital General Universitario de Alicante Doctor Balmis), Juan Cosı́n-Sales(Hospital Arnau de Vilanova), Vicente Pallarés‐Carratalá, José Ramón González‐Juanatey(Centro de Investigación en Red en Enfermedades Cardiovasculares), L. Masana(Universitat Rovira i Virgili), Esteban López de Sá(Hospital Universitario La Paz), Vivencio Barrios(Apple (Israel)), Manuel Anguita(Instituto Maimónides de Investigación Biomédica de Córdoba), Ángel Cequier(Bellvitge University Hospital)
Cited by 21
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k